Literature DB >> 9260999

Hypopharyngeal cancer patient care evaluation.

H T Hoffman1, L H Karnell, J P Shah, S Ariyan, G S Brown, W E Fee, A G Glass, H Goepfert, R H Ossoff, A M Fremgen.   

Abstract

A survey was conducted to identify demographics and standards of care for treatment of hypopharyngeal squamous cell carcinoma in the United States. Data were accrued from voluntary submission of cancer registry and medical chart information from 769 hospitals representing 2939 cases diagnosed from 1980 to 1985 and 1990 to 1992. Clinical findings, diagnostic procedures employed, treatment practices, and outcome are presented. Overall, 5-year disease-specific survival was 33.4%, which segregated to 63.1% (stage I), 57.5% (stage II), 41.8% (stage III), and 22% (stage IV). Survival was best for patients treated with surgery only (50.4%), similar with combined surgery and irradiation (48%), and worse with irradiation only (25.8%). This analysis provides a standard to which current treatment practice and future clinical trials may be compared.

Entities:  

Mesh:

Year:  1997        PMID: 9260999     DOI: 10.1097/00005537-199708000-00001

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  34 in total

1.  Extent of surgical intervention in case of N0 neck in head and neck cancer patients.

Authors:  Jatin P Shah
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-01-09       Impact factor: 2.503

2.  Pyriform sinus squamous cell carcinoma: oncological outcomes in good responders of induction chemotherapy-based larynx preservation protocols.

Authors:  Zacharias Vourexakis; Anne-Marie Le Ridant; Pavel Dulguerov; François Janot
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-05-23       Impact factor: 2.503

3.  Effect of microRNA-203 on tumor growth in human hypopharyngeal squamous cell carcinoma.

Authors:  Ru Wang; Jugao Fang; Hongzhi Ma; Lin Feng; Meng Lian; Fan Yang; Haizhou Wang; Qi Wang; Xiaohong Chen
Journal:  Mol Cell Biochem       Date:  2015-04-04       Impact factor: 3.396

4.  A nomogram for predicting occult lymph node metastasis in early hypopharyngeal cancer with cN0.

Authors:  Xiaohui Yuan; Chi-Yao Hsueh; Ming Zhang; Lei Tao; Liang Zhou
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-02-10       Impact factor: 2.503

5.  Closure of defects after resection of tumors of the oral cavity and the pharynx: medium- to long-term oncologic and functional results with the myocutaneous platysma flap.

Authors:  Julian Künzel; Heinrich Iro; Georgios Psychogios; Johannes Zenk; Michael Koch
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-02-09       Impact factor: 2.503

6.  Incidence and localization of abnormal mucosa findings in patients consulting ENT outpatient clinics and data analysis of a cancer registry.

Authors:  J Löhler; A O H Gerstner; F Bootz; L E Walther
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-10-10       Impact factor: 2.503

7.  Hypopharyngeal cancer: looking back, moving forward.

Authors:  D Day; A R Hansen; L L Siu
Journal:  Curr Oncol       Date:  2016-08-12       Impact factor: 3.677

8.  [Prevalence of abnormal mucosal findings in patients in HNO practices].

Authors:  J Löhler; A O H Gerstner; F Bootz; H Heinritz; A Fryen; G Fryen; N Holstein; A Lingg; J Kleeberg; W Langhoff; G Rösch; A Hanisch; E Schneeberg; D Heinrich; L E Walther
Journal:  HNO       Date:  2012-03       Impact factor: 1.284

9.  Association of Positive Initial Margins With Survival Among Patients With Squamous Cell Carcinoma Treated With Total Laryngectomy.

Authors:  Patrick Tassone; Corey Savard; Michael C Topf; William Keane; Adam Luginbuhl; Joseph Curry; David Cognetti
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-11-01       Impact factor: 6.223

10.  Supracricoid hemilaryngopharyngectomy for selected pyriform sinus carcinoma patients--a retrospective chart review.

Authors:  George X Papacharalampous; Georgios P Kotsis; Petros V Vlastarakos; Alexandros Georgolios; Ioannis Seggas; Ioannis E Yiotakis; Leonidas Manolopoulos
Journal:  World J Surg Oncol       Date:  2009-08-11       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.